集成的生物化学和细胞验证SIP0401作为一种同型偏好的PDE4B抑制剂
Uthman M Alghamdi1, Ayed A Dera2
1Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, King Khalid University, Abha, Saudi Arabia.
Molecular biology reports
|March 10, 2026
概括
研究人员发现了SIP0401,一种新型的基化酶-4B (PDE4B) 抑制剂. 这种小分子通过选择性向PDE4B和调节cAMP水平,显示出治疗炎症的潜力.
科学领域:
- 药用化学 医学化学
- 药理学 药理学是指药理学的学科.
- 分子生物学分子生物学
背景情况:
- 固-4B (PDE4B) 是细胞内循环腺单酸盐 (cAMP) 水平的关键调节剂,也是促炎性细胞因子生产的驱动因素.
- 开发选择性PDE4B抑制剂对于扩大对抗炎症疾病的治疗策略至关重要.
- 一种新型小分子SIP0401被确定并验证为潜在的PDE4B抑制剂.
研究的目的:
- 为了发现和验证新的小分子抑制剂,以提高异型选择性向二酶-4B (PDE4B).
- 利用一个集成的in silico管道,包括药模拟和分子对接,以优先考虑候选药物.
- 为了评估生物化学和细胞活性,以及已识别的抑制剂的选择性和安全性,SIP0401.1.
主要方法:
- 针对PDE4B催化域,使用虚拟选和干效率引导过来识别SIP0401.1.
- 实验验证包括生物化学测试 (PDE-GloTM,HTRF cAMP,差异扫描度测试) 和细胞测试 (cAMP,TNF-α ELISA,细胞毒性).
- 评估了对PDE4A,PDE4C和PDE4D的异形选择性,以及对聚合,溶解性和潜在的光酶干扰的评估.
主要成果:
- 在SIP0401中,PDE4B具有强烈的抑制作用,IC50值在纳米分子范围 (282-338.4nM) 中.
- 该化合物对PDE4B比其他PDE4异型 (PDE4A/C/D) 具有适度的选择性,IC50在1.16-1.97μM之间.
- 在细胞分析中,SIP0401有效地增加了cAMP水平,并抑制了THP-1巨细胞中TNF-α的产生,在BEAS-2B细胞中具有有利的细胞毒性.
结论:
- 通过结构引导虚拟查识别的SIP0401显示了对PDE4B的有希望的中等生化选择性.
- 该化合物的已证明的细胞活性和有利的物理化学特性支持其进一步发展和体内评估.
- SIP0401代表了开发针对PDE4B介导炎症通路的新疗法的潜在主要化合物.
相关概念视频
01:23Dipeptidyl Peptidase 4 Inhibitors
836
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
836
01:42Phosphoinositides and PIPs
10.4K
Phosphoinositides are a group of phospholipids containing a glycerol backbone with two fatty acid chains and a phosphate attached to a myoinositol sugar ring. The inositol head group extends into the cytoplasm, where it is modified by adding phosphate groups to form phosphatidylinositol phosphates or PIPs.
Different phosphoinositides are synthesized and recruited on the cytosolic face of the plasma membrane. The localization of specific phosphoinositides concentrated in separate membrane...
Different phosphoinositides are synthesized and recruited on the cytosolic face of the plasma membrane. The localization of specific phosphoinositides concentrated in separate membrane...
10.4K
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
86
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450...
86
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
678
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
678